These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26609872)

  • 1. New antiarrhythmic targets in atrial fibrillation.
    Voigt N; Heijman J; Dobrev D
    Future Cardiol; 2015; 11(6):645-54. PubMed ID: 26609872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New directions in antiarrhythmic drug therapy for atrial fibrillation.
    Heijman J; Voigt N; Dobrev D
    Future Cardiol; 2013 Jan; 9(1):71-88. PubMed ID: 23259476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antiarrhythmic drugs for prevention of atrial fibrillation.
    Goldstein RN; Stambler BS
    Prog Cardiovasc Dis; 2005; 48(3):193-208. PubMed ID: 16271945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electropharmacological effects of antiarrhythmic drugs on atrial fibrillation termination. Part I: Molecular and ionic fundamentals of antiarrhythmic drug actions.
    Calò L; Sciarra L; Lamberti F; Loricchio ML; Castro A; Bianconi L; Pandozi C; Gaita F; Santini M
    Ital Heart J; 2003 Jul; 4(7):430-41. PubMed ID: 14558293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis.
    Heijman J; Algalarrondo V; Voigt N; Melka J; Wehrens XH; Dobrev D; Nattel S
    Cardiovasc Res; 2016 Apr; 109(4):467-79. PubMed ID: 26705366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial fibrillation: recent advances in understanding the role of microRNAs in atrial remodeling with an electrophysiological overview.
    Poudel P; Xu Y; Cui Z; Sharma D; Tian B; Paudel S
    Cardiology; 2015; 131(1):58-67. PubMed ID: 25871909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression.
    Heijman J; Voigt N; Nattel S; Dobrev D
    Circ Res; 2014 Apr; 114(9):1483-99. PubMed ID: 24763466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial fibrillation: mechanisms, therapeutics, and future directions.
    Pellman J; Sheikh F
    Compr Physiol; 2015 Apr; 5(2):649-65. PubMed ID: 25880508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhythm control of atrial fibrillation in heart failure.
    Heijman J; Voigt N; Abu-Taha IH; Dobrev D
    Heart Fail Clin; 2013 Oct; 9(4):407-15, vii-viii. PubMed ID: 24054474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive insight of novel antioxidant therapies for atrial fibrillation management.
    Orenes-Piñero E; Valdés M; Lip GY; Marín F
    Drug Metab Rev; 2015 Aug; 47(3):388-400. PubMed ID: 27412960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy.
    Aguilar M; Nattel S
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):432-40. PubMed ID: 25923324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interatrial conduction in the mechanisms of atrial fibrillation: from anatomy to cardiac signals and new treatment modalities.
    Platonov PG
    Europace; 2007 Nov; 9 Suppl 6():vi10-6. PubMed ID: 17959684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.
    Li D; Sun H; Levesque P
    Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):64-75. PubMed ID: 19149545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.
    Shiroshita-Takeshita A; Sakabe M; Haugan K; Hennan JK; Nattel S
    Circulation; 2007 Jan; 115(3):310-8. PubMed ID: 17224477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial remodeling and novel pharmacological strategies for antiarrhythmic therapy in atrial fibrillation.
    Jost N; Kohajda Z; Kristóf A; Kovács PP; Husti Z; Juhász V; Kiss L; Varró A; Virág L; Baczkó I
    Curr Med Chem; 2011; 18(24):3675-94. PubMed ID: 21774760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electropharmacological effects of antiarrhythmic drugs on atrial fibrillation termination. Part II: New insights into the electrophysiological mechanisms of atrial fibrillation termination.
    Calò L; Sciarra L; Lamberti F; Loricchio ML; Castro A; Bianconi L; Pandozi C; Gaita F; Santini M
    Ital Heart J; 2003 Jul; 4(7):442-7. PubMed ID: 14558294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational modeling: What does it tell us about atrial fibrillation therapy?
    Grandi E; Dobrev D; Heijman J
    Int J Cardiol; 2019 Jul; 287():155-161. PubMed ID: 30803891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized therapy in patients with atrial fibrillation: new look at atrial fibrillation.
    Shenasa M; Soleimanieh M; Shenasa F
    Europace; 2012 Nov; 14 Suppl 5():v121-v124. PubMed ID: 23104908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pharmacological therapies for atrial fibrillation.
    Bagwe S; Leonardi M; Bissett J
    Curr Opin Cardiol; 2007 Sep; 22(5):450-7. PubMed ID: 17762547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.
    Rosa GM; Bianco D; Parodi A; Valbusa A; Zawaideh C; Bizzarri N; Ferrero S; Brunelli C
    Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1751-64. PubMed ID: 25349898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.